Key result
PAI-1 emerges as a novel vascular risk factor and potential target for vascular disease prevention.
Answers are grounded in this paper and cite their sources.
Fibrinolysis plays a crucial role in the development of vascular disease. The interface between the plasminogen activators and inhibitors determines the fibrinolytic potential of human blood. In addition to fibrin degradation, fibrinolytic system components modulate several complex biological events such as angiogenesis, tumorigenesis, arteriosclerosis and cellular migration. Recent experimental and clinical data indicated that PAI-1 as a novel vascular risk factor. In this concise review, we will examine the accumulating evidence suggesting that there is an intricate relationship between these systems which may provide new therapeutic strategies for prevention of vascular disease.
No takes yet. Share an insight, caveat, or question.
A 2005 study conducted a review in Vascular disease. Plasminogen-activator inhibitor 1 (PAI-1) was evaluated. Plasminogen-activator inhibitor 1 (PAI-1) is examined in this review as a novel vascular risk factor and potential target for preventing vascular disease (no quantitative results reported).
Synapse has enriched 10 related papers. Consider them for comparative context: